CDNA at a glance
CareDx, Inc. (CDNA, SEC CIK 1217234) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 16, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding CareDx, Inc. (CDNA) shares worth $595.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bickerstaff George on August 5, 2026 of 20,000 shares at $46.28 per share.
- In the last 90 days, CDNA insiders reported 0 open-market purchases ($0) and 9 open-market sales ($9.4M) on Form 4, a net sale of $9.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $379.8M
- +13.8% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$9.4M
- 13F holders
- 31 funds
- $595.0M · +1 vs prior quarter
- Latest 8-K
- Sep 16, 2026
- Item 2.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Specialized molecular diagnostic testing and digital pharmacy solutions for transplant patients
- Expanded patient and digital solutions revenue by 31%, driven by pharmacy sales growth and wider Ottr software deployment
- Strategic share repurchase programs totaling $88 million in 2025, reflecting confidence despite net loss of $21 million
- Testing services volume increased 14% to approximately 200,000 tests, with overall revenue growth of 14% to $380 million
- Noteworthy litigation expense reversal in 2024 due to favorable patent ruling, partially offset by 2025 Securities Class Action settlement
Risk Factors
- MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025
- Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision
- Dependency on single California lab facility; if inoperable, inability to perform core tests AlloSure Kidney, AlloMap Heart, HeartCare, and AlloSure Lung
- Competitive risk from rapid technological evolution in transplantation diagnostics, could render CareDx’s AlloSure and AlloMap tests obsolete
- Concentration risk around Medicare Advantage payer dispute over denied and recouped claims, creating financial uncertainty and potential repayment obligations
Management Discussion & Analysis
- Revenue recognition includes testing services, product sales, patient and digital solutions; testing revenue reduced by $3.5M refund reserve in 2025
- No profitability or margin figures disclosed in the provided text
- Management sees no goodwill or intangible asset impairments as of Dec 31, 2025; foreign operations risks noted but no quantified impact or guidance
AI summary of the CDNA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New Medicare compliance trigger: 2026 legislation requires private-payor rate reporting to CMS during May–July 2026
- Medicare concentration: testing revenue 37% and total revenue 30% from Medicare during the quarter
- Regulatory coverage risk: Final LCD effective August 30, 2026 preserves coverage but imposes defined criteria for transplant testing
- Competitive adoption risk: Natera and Eurofins offer commercially available molecular transplant-surveillance diagnostics
- Profitability risk: $110.6 million quarterly net income versus $505.4 million accumulated deficit
AI summary of the CDNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.01: Completion of Acquisition or Disposition of Assets
- CareDx amending its July 7, 2026 8-K reporting completion of Naveris acquisition
- Acquisition represents expansion through Naveris, a Delaware corporation
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation current as of June 30, 2026
- Investor-relevant business information available on CareDx’s website
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, formally released July 30, 2026
- Financial details and management commentary contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- CareDx announced closing of the Eurobio Transaction on June 30, 2026
- CareDx announced closing of the Naveris Transaction on July 1, 2026
Item 2.01: Completion of Acquisition or Disposition of Assets
- CareDx received $171.7 million cash from Eurobio for CareDx AB and kitted laboratory products assets
- Divestiture removes the kitted laboratory products business and related software from CareDx’s portfolio
AI summaries of CDNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CDNA
Don't miss the next CDNA filing
- Alerts as it files. A push when CDNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CDNA, by share count.
- Ask anything. An AI agent that reads every CDNA filing and answers with sources.
CDNA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Goldberg Michael | A | Oct 2, 2026 | 588 | - |
| Hanna John Walter JR | F | Oct 1, 2026 | 8,511 | $66.23 |
| Novack Jeffrey Adam | F | Oct 1, 2026 | 997 | $66.23 |
| Meng Jessica | F | Oct 1, 2026 | 2,619 | $66.23 |
| Kennedy Keith | F | Oct 1, 2026 | 3,018 | $66.23 |
| Kennedy Keith | F | Sep 12, 2026 | 8,220 | $52.37 |
| Meng Jessica | F | Sep 12, 2026 | 6,688 | $52.37 |
| Bickerstaff George | Sell | Aug 5, 2026 | 20,000 | $46.28 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $280.3M | $333.8M | $379.8M |
| Operating Income | -$203.4M | $40.8M | -$30.8M |
| Net Income | -$190.3M | $52.5M | -$21.4M |
| Op. Margin | -72.5% | 12.2% | -8.1% |
| Net Margin | -67.9% | 15.7% | -5.6% |
| Balance Sheet | |||
| Total Assets | $466.8M | $491.1M | $413.2M |
| Equity | $261.3M | $378.4M | $303.1M |
| ROE | -72.8% | 13.9% | -7.0% |
| Per Share | |||
| EPS | $-3.54 | $0.93 | $-0.40 |
| Cash Flow | |||
| Operating CF | - | $38.0M | $42.0M |
Source: XBRL data in CareDx, Inc. (CDNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CDNA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $595.0M |
| Q1 2026 | 30 | $351.2M |
| Q4 2025 | 28 | $390.4M |
| Q3 2025 | 28 | $301.5M |
| Q2 2025 | 29 | $464.9M |
| Q1 2025 | 26 | $361.4M |
| Q4 2024 | 22 | $397.5M |
| Q3 2024 | 19 | $389.9M |
- Morgan Stanley+348.9K (+82%)
- BlackRock+292.6K (+6%)
- D.E. Shaw & Co+262.8K (+30%)
- Two Sigma Investments+170.4K (+74%)
- Vanguard Portfolio Management LLC+138.1K (+16%)
- State Street Corp−291.5K (-11%)
- Dimensional Fund Advisors−280.8K (-19%)
- ARK Investment Management−274.0K (-12%)
- AQR Capital Management−104.8K (-30%)
- Invesco Ltd−37.7K (-8%)
- Millennium Management+73.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 213 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CDNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
Related Health Care companies
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
CDNA SEC filings: frequently asked questions
Are CDNA insiders buying or selling?
In the last 90 days, CareDx, Inc. (CDNA) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $9.4 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CDNA stock?
As of June 30, 2026, the largest CareDx, Inc. (CDNA) holders among the 13F filers tracked by SignalX were BlackRock ($137.2 million), State Street Corp ($70.4 million), Vanguard Capital Management LLC ($62.6 million), ARK Investment Management ($55.7 million), Renaissance Technologies LLC ($35.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CDNA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40. The figures come from the XBRL data in the 10-K.
What are the main risks in CDNA's latest 10-K?
In the 10-K filed February 25, 2026, CareDx, Inc. (CDNA) flagged: MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025. Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision. (AI summary of the Risk Factors section.)
What did CDNA report in its latest 8-K?
CareDx, Inc. (CDNA) filed an 8-K on September 16, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets). CareDx amending its July 7, 2026 8-K reporting completion of Naveris acquisition.
What are the latest CDNA SEC filings?
CareDx, Inc. (CDNA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 16, 2026 and a Form 4 insider filing on October 5, 2026.
What is CDNA's SEC CIK number?
CareDx, Inc. (CDNA)'s SEC Central Index Key (CIK) is 1217234. EDGAR lists every CDNA filing under that number.
Ask anything about CDNA
The research agent reads CDNA's filings, financials, insider trades and 13F holders, then answers with sources.